CLV – UBS rates the stock as Upgrade to Buy

UBS upgrades Clover Corp to Buy from Neutral rating with the target price dropping to $2 from $2.10. 

The broker views the stock as a recovery play offering a best-of-breed product and a unique growth story despite a covid-hit weak result with revenues down -22% versus last year.

The company’s FY21 revenue guidance also implies a -16-37% downgrade to UBS’s second-half expectations. Even so, the broker expects a gradual recovery with FY20 revenues and net profit expected to return by FY23.

Sector: Health Care Equipment & Services.

 

Target price is $2.00.Current Price is $1.46. Difference: $0.54 – (brackets indicate current price is over target). If CLV meets the UBS target it will return approximately 27% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →